Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Melanoma in 2011

A new paradigm tumor for drug development

Nature Reviews Clinical Oncology volume 9, pages 74–76 (2012)Cite this article

Subjects

Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Dual targeting of the MAPK and PI3K pathways in melanoma treatment.

References

  1. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Infante, J. R. et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. J. Clin. Oncol. 29 (Suppl.), CRA8503J (2011).

    Article  Google Scholar 

  4. Carvajal, R. D. et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 305, 2327–2334 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388–1397 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer. doi:10.1016/j.ejca.2011.09.028

Download references

Author information

Authors and Affiliations

  1. Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94805, Paris-Sud, France

    Alexander M. M. Eggermont & Caroline Robert

Authors
  1. Alexander M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. M. Eggermont.

Ethics declarations

Competing interests

The authors declare they are consultants for Bristol-Myers Squibb, Glaxo-Smithkline, Merck and Roche and receive research honoraria from Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eggermont, A., Robert, C. A new paradigm tumor for drug development. Nat Rev Clin Oncol 9, 74–76 (2012). https://doi.org/10.1038/nrclinonc.2011.201

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.201

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer